Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis
Valtis, Yannis K. , Sandhu, Karamjeet , Zhang, Amy , Miller, Katharine, Oliai, Caspian , Lill, Georgia R. , Kopmar, Noam E. , Connor, Matthew P. , Solh, Melhem , Guzowski, Caitlin, Tan, Virginia, Jeyakumar, Nikeshan , Hoeg, Rasmus T. , Koura, Divya, Gatell, Vivian Irizarry , O'Dwyer, Kristen M., Moore, Jozal , Ulrickson, Matthew L. , Al-Darobi, Ali, Byrd, Ken, Tsai, Stephanie, O’Connor, Timothy E. , McCauley, Ross , Mohty, Razan , Sutherland, Katherine, Muffly, Lori , Frey, Noelle, Muffly, Lori , Faramand, Rawan , Hill, LaQuisa C. , Muhsen, Ibrahim N. , Othman, Tamer , Luskin, Marlise R , Chen, Evan , Oliai, Caspian H , Cassaday, Ryan D. , Logan, Aaron C , Hilal, Talal , Park, Jae H. , Leonard, Jessica T , Srinagesh, Hrishikesh K. , Kumaran, Muthu Sendhil , Dykes, Kaitlyn C. , Stock, Wendy , Jackson, Clayton, Oluwole, Olalekan O. , Dholaria, Bhagirathbhai , O'Dwyer, Kristin , Wang, Eunice S. , Jamy, Omer , Roloff, Gregory W. , Aldoss, Ibrahim , Shah, Bijal , Frey, Noelle

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2715-2715

10.1182/blood-2025-2715 Get It

Abstract Introduction Obecabtagene autoleucel (obe-cel) and brexucabtagene autoleucel (brexu-cel) are CD19 targeted chimeric antigen receptor T cell (CAR-T) therapies, approved for the treatment of adults with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Mechanistic differences between obe-cel and brexu-cel including differing costimulatory domains (4-1BB vs. CD28), CD19 binding domains (intermediate vs. high affinity) and split dose (Days 1 and 10) vs. single infusion may impact in-vivo cellular kinetics that translate into variant clinical outcomes. In pivotal trials, obe-cel resulted in lower rates of severe cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) compared to brexu-cel with comparable efficacy (Roddie et al., NEJM 2025; Shah et al., Lancet 2021). Real-world utilization and outcomes with obe-cel are unknown given the relatively recent approval. Methods The ROCCA database, comprising real world data from patients (pts) with r/r ALL treated at 40 North American institutions was utilized in this analysis. Pts with r/r ALL were eligible if they were apheresed for obe-cel since its approval (11/8/2024) or brexu-cel over a comparable period (since 8/1/24) and had at least 30 days of follow up. Data cut off was 7/15/2025. CRS/ICANS were graded per ASTCT criteria. Measurable residual disease (MRD) was assessed by flow cytometry and/or next generation sequencing per institutional standards. Results 38 pts have undergone apheresis for obe-cel (36 infused, all received both infusions) and 54 (53 infused) for brexu-cel over the study period. Pts in the obe-cel and brexu-cel cohorts had the following baseline characteristics: median age, 47 vs. 39 years; ECOG 2+, 15% vs. 26%; Ph+ disease, 24% vs 13%; KMT2Ar, 0 vs. 4%; TP53m, 11% vs 11%, and hypodiploid karyotype, 5% vs 6%. The following prior treatment patterns were observed: median lines of therapy before CAR-T 3 vs. 3; prior SCT 24% vs. 30%, prior blinatumomab 68% vs. 46%, prior inotuzumab 45% vs. 30%. At apheresis, active disease (>5% bone marrow blasts) was present in 47% vs. 55% of obe-cel and brexu-cel pts, respectively; the remainder were in CR (with 18% vs. 22% in MRD- CR, respectively). Among obe-cel (n= 35 [92% of cohort]) and brexu-cel (21 [38% of cohort] pts with disease re-assessment prior to lymphodepletion (LD), 31% vs. 43% had active BM disease, respectively; few pts (24% vs. 17%) had >20% marrow disease burden prior to LD. CAR-mediated toxicity differed significantly between the cohorts. CRS occurred in 56% of obe-cel pts compared to 94% of brexu-cel pts (p < 0.0001). There were no Gr3+ CRS events among the obe-cel pts; 3 (6%) brexu-cel pts had Gr3+ CRS (p = 0.27). ICANS occurred in 17% of obe-cel pts vs. 51% of brexu-cel pts (p = 0.001). Gr3+ ICANS occurred in 6% of obe-cel vs. 32% of brexu-cel pts (p = 0.0027). Among the obe-cel pts, CRS occurred in 31% after the first infusion and 46% after the second; ICANS occurred in 3% after the first infusion and 15% after the second. Prolonged Gr4 neutropenia (ANC < 500 cells/uL beyond day 30 from infusion) occurred in 24% of obe-cel vs. 28% of brexu-cel pts (p = 0.73). Deaths within the first 28 days of infusion occurred in 0 obe-cel pts and 4 brexu-cel pts (2 of infection, 1 of infection/brain bleed, and 1 of liver failure in the setting of Gr4 CRS and HLH). Response rates were high and did not significantly differ between cohorts (p = 0.85). Among the 31 obe-cel pts with available response data, 25 (81%) achieved an MRD- CR/CRi, 3 (10%) had an MRD+ CR/CRi, 2 (6%) had a CR/CRi with unknown MRD, and 1 (3%) did not respond. Among 41 brexu-cel pts with available response data, 33 (80%) had an MRD- CR/CRi, 4 (10%) an MRD+ CR/CRi, and 4 (10%) CR/CRi with unknown MRD. Conclusion Pts selected for obe-cel apheresis were similar to those for brexu-cel over the study period (noting that not all centers had access to obe-cel during this time). Similar to clinical trial results, obe-cel was associated with lower rates of CRS/ICANS. Rates of MRD-negative CR were high and did not differ between cohorts. A larger sample and longer follow up are required for further analyses; we anticipate a cohort of ~75 obe-cel treated pts by the annual meeting and will provide updated data.
Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study
Kittai, Adam S. , Hampel, Paul J. , Fu, Qianhong, Zhao, Danni , Mbah, Olive , Sawas, Ahmed , Wagner, Benjamin , Myers, Rachel A. , Beuge, Derrick van, Maglinte, Gregory A. , Rhodes, Joanna , Wang, Xiaoliang , Karwa, Smriti , Wagner, Benjamin, Myers, Rachel, Beuge, Derrick van, Seymour, Erlene Kuizon , Barrientos, Jacqueline C.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2720-2720

10.1182/blood-2025-2720 Get It

Abstract Background The treatment (tx) landscape for chronic lymphocytic leukemia (CLL) has evolved, with National Comprehensive Cancer Network (NCCN) guideline-preferred novel therapies (NTs), such as acalabrutinib, zanubrutinib, and venetoclax-based regimens, now preferred over ibrutinib and chemoimmunotherapy (CIT) in front-line (1L) settings. We previously showed that patients (pts) from different racial/ethnic groups may not have equitable access to NTs. Here, we examined racial/ethnic inequities in 1L NT utilization among US pts with CLL and potential social determinants of health (SDOH) drivers of these inequities. Methods This retrospective cohort study utilized the US-based, electronic health record-derived de-identified Flatiron Health Research Database, linked to neighborhood (US Census track or block group) data from American Community Survey and Agency for Healthcare Research and Quality datasets. Eligible pts included adults with CLL who started 1L tx 01/01/2019-07/31/2024. The primary outcome was receipt of 1L therapy (CIT vs preferred NTs, ibrutinib vs preferred NTs), with NCCN guideline-preferred NTs (v2.2023-v3.2025) as a reference. Associations between race/ethnicity (White, Black, Hispanic) and 1L tx types were assessed using logistic regressions, adjusting for age, sex, year of 1L start, immunoglobulin heavy chain variable region status, and del17p/TP53 status. To better understand which SDOH factors contribute to racial and ethnic inequities in tx utilization, we performed mediation analysis using Multiple Mediation Analysis implemented through nonlinear multiple additive regression tree models. Individual-level (Eastern Cooperative Oncology Group status, practice type, insurance) and 20 area-level SDOH factors measuring social deprivation (defined as limited access to economic, social, neighborhood, physical, or healthcare resources) were assessed as potential mediators. Results Of the 4452 pts included in the study, 3717 were White (83%), 371 were Black (8%), 209 were Hispanic (5%), and 155 were Other race (4%). Black and Hispanic pts were more likely to live in neighborhoods with higher social deprivation, such as residential segregation (predominant race/ethnicity in the area: White, Black, Hispanic, Diverse), with no internet access, no vehicle ownership, and no health insurance coverage. Overall, 37% of pts received a preferred NT, highest among White (38%) pts, followed by Black (35%) and Hispanic (26%) pts. Compared with White pts, Hispanic pts were more likely to receive CIT than preferred NTs (adjusted odds ratio [aOR] 2.12; 95% confidence interval [CI] 1.46-3.09); Black (aOR 1.44; 95% CI 1.05-1.97) and Hispanic pts (aOR 1.83; 95% CI 1.17-2.85) were more likely to receive ibrutinib than preferred NTs. Pts living in areas with the highest social deprivation were less likely than their counterparts in lowest social deprivation neighborhoods to receive preferred NTs. Specifically, residence in predominantly Black or Hispanic neighborhoods (26% or 27% vs 39% predominantly White), areas with lowest socioeconomic status (32% vs 40%), and neighborhoods with the lowest levels of internet access (32% vs 39%), vehicle ownership (32% vs 39%), and health insurance coverage (34% vs 41%) was associated with lowest receipt of preferred NTs. In the mediation analysis, individual- and area-level SDOH factors explained 94.4% (95% CI 2.9-185.9) of the observed Black-White inequity in receipt of ibrutinib versus preferred NTs; residential segregation appeared to be the most important mediator (59.7%; 95% CI −3.5 to 123.0). Similarly, the Hispanic-White inequity in receipt of preferred NTs was driven by the combined effect of area-level SDOH and individual-level variables (88.5%; 95% CI 45.6-131.3), with residential segregation as the main driver (48.3%; 95% CI 10.7-85.9), followed by practice setting (9.8%; 95% CI −3.5 to 23.1). In contrast, measured SDOH factors did not explain the inequity in receipt of CIT versus preferred NTs between Hispanic and White pts (21.5%; 95% CI −8.3 to 51.4), suggesting that other factors may contribute to the observed inequities. Conclusion Black and Hispanic pts with CLL were less likely than White pts to receive preferred NTs. A significant proportion of these disparities was explained by area-level SDOH, particularly residential segregation. These findings underscore the need to address structural barriers to ensure equitable access to emerging, guideline-recommended treatments.
Real-world treatment patterns and biomarker utilization among patients aged ≥65 years with CLL/SLL from 2020 to 2024
Hampel, Paul J. , Kardel, Peter , Sheetz, Caitlin , Das, Ashis , Fu, Qianhong, Ding, Lee, Maglinte, Gregory A. , Ermann, Daniel A. , Wang, Xiaoliang , Das, Ashis, Ding, Lee, Seymour, Erlene Kuizon , Jacobs, Ryan W.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2723-2723

10.1182/blood-2025-2723 Get It

Abstract Background Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in US adults and incidence increases with age. Although the treatment (tx) landscape has evolved, it is unclear whether tx selection differs for older patients (pts), given concerns around comorbidities, toxicity, and efficacy. There is a need to better understand pt characteristics, tx patterns, and biomarker use among pts aged ≥65 yrs with CLL/SLL in the current therapeutic era. Methods A retrospective longitudinal study was conducted using the de-identified 100% Medicare Fee-for-Service (FFS) Research Identifiable Files. Included pts were diagnosed with CLL/SLL at age ≥65 and initiated first-line (1L) tx 1/1/2020-9/30/2024 (with ≥12 mo in database prior to 1L tx start). Index date was defined as date of 1L tx start, and pts were followed to death, end of Medicare enrollment, or study end, whichever occurred first. 1L tx was defined as any CLL pharmacologic tx within the first 90 days of index date. Tx utilization was summarized as the number and proportion of pts who received each tx at each line. Descriptive statistics were used to summarize demographic and social characteristics and baseline comorbidities, in all pts and by 1L tx. Proportion and timing of documented biomarker orders any time prior to index were summarized by test type (CLL fluorescence in situ hybridization [FISH], TP53 DNA sequencing and immunoglobulin heavy chain variable region [IGHV] test) and by 1L tx. Results Of the 21,008 pts included, median age was 76.4 yrs at 1L tx, with 43% of pts aged 65-74 yrs, 43% aged 75-84 and 14% aged ≥85. The majority of pts were male (58%) and White (91%). About 8% and 9% of pts had dual eligibility status and low-income subsidy, respectively. Median Charlson Comorbidity Index (CCI) was 4 (range: 1-21), with 40% of pts having CCI ≥5. Covalent Bruton tyrosine kinase inhibitor (cBTKi) monotherapies (mono) were most common at 1L tx (41%), including 10% zanubrutinib (zanu), 15% ibrutinib (ibr), and 16% acalabrutinib (acala). B-cell lymphoma 2 (BCL2)+anti-CD20 monoclonal antibody (mAb) was less common (11%), and chemoimmunotherapy (CIT) was used by 13% of pts, mostly BR (8%) and FCR (3%). Other less common tx included cBTKi+anti-CD20mAb (6%) or cBTKi+BCL2 therapies (1%). Among remaining pts, most received anti-CD20mAb (22%). The use of cBTKi mono increased from 41.7% in 2020 (ibr 30.6%; acala 11.1%) to 47.6% in 2024, driven by increased use of zanu (27.8%; acala 15.7%; ibr 4.2%). BCL2+anti-CD20mAb increased from 9.2% in 2020 to 12.6% in 2024. Pts treated with cBTKi mono were older than those with BCL2+anti-CD20mAb (median age 77.2 vs 74.5), and more likely to have dual eligibility status (10% vs 4%) or low-income subsidy (11% vs 5%). More pts who received zanu mono had CCI ≥5 (39%) versus acala (36%), ibr (35%), or BCL2+anti-CD20mAb (32%). Pts with BCL2+anti-CD20mAb were less likely to have diabetes (23% vs 26%), congestive heart failure (CHF; 16% vs 19%), chronic pulmonary disease (23% vs 27%), and renal diseases (23% vs 27%). Pts with ibr were less likely to have myocardial infarction (29% vs 34%), coronary artery disease (22% vs 25%), CHF (16% vs 19%), and atrial fibrillation (12% vs 18%). Overall, 69% of pts had FISH testing prior to 1L tx, but test orders for TP53 (12%) or IGHV (28%) status were infrequent. Pts with ibr had the lowest rates of TP53 tests (6%), whereas pts with CIT had the lowest rates of IGHV tests (16%). The timing of tests showed a binomial distribution where most pts received FISH, TP53, or IGHV tests either ≤60 days prior to 1L tx (46%, 50%, 33%), or >1 yr before 1L tx (30%, 22%, 43%). Among pts who received ≥2 lines of therapy for CLL (n=4428; 21%), cBTKi mono was the most common in 2L (41%), including 14% zanu, 17% acala, and 10% ibr. CIT and BCL2+anti-CD20mAb were used in 12% and 9% of pts, respectively. Only 634 (3%) pts had 3L+ tx, of whom 33% received cBTKi mono, including 16% zanu, 12% acala, and 5% ibr (5%). Conclusion This large real-world study found that cBTKi mono was the most common 1L tx choice among pts aged ≥65 with CLL/SLL, with increased use of next-generation cBTKi. Pts with more baseline comorbidities were less likely to receive ibr or BCL2-based tx. FISH testing was not performed in nearly one-third of pts, and most pts did not have TP53 or IGVH sequencing prior to tx. Future studies are needed to continue to evaluate evolving tx paradigms in older pts with CLL/SLL.
Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts
Mehta-Shah, Neha, Allen, Pamela, Cohen, Jonathon B. , Lossos, Izidore S. , Pongas, Georgios , Flowers, Christopher R. , Ruan, Jia , Mehta–Shah, Neha , Larson, Melissa C. , Mou, Eric , Bennani, N. Nora , Wallace, Danielle, Malpica, Luis , Martin, Peter, Habermann, Thomas M. , Wang, Yucai , Nze, Chijioke , Witzig, Thomas E. , Syrbu, Sergei , Jaye, David L. , Nastoupil, Loretta J. , Cerhan, James R. , Feldman, Andrew L. , Maurer, Matthew J.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5439-5439

10.1182/blood-2025-5439 Get It

Abstract Background Previous studies in aggressive B-cell lymphoma demonstrate that patients with shorter diagnosis-to-treatment intervals (DTI) represent those with higher risk disease. This suggests that patients enrolled in clinical trials may carry a selection bias as they often have longer DTI than patients in the general population. This has important implications for clinical research design and the generalizability of clinical trials in aggressive lymphomas. However, the prognostic implications of DTI have not been evaluated in peripheral T-cell lymphomas (PTCL). Therefore, we examined DTI and its association with clinical factors and outcomes in a prospective observational cohort of patients with PTCL from the United States within the LEO (Lymphoma Epidemiology and Outcomes) and MER (University of Iowa and Mayo Clinic Specialized Programs of Research Excellence Molecular Epidemiology Resource). Patients and Methods We evaluated patients enrolled to the MER (2002-2015) and LEO (2015-2020) cohorts with the following forms of PTCL: PTCL-not otherwise specified (PTCL-NOS, n=217), nodal T-follicular helper (TFH) cell lymphoma (nTFHL, n=153), anaplastic large cell lymphoma (ALCL), ALK positive (ALCL, ALK+, n=74), ALCL, ALK negative (ALCL, ALK-, n=95), enteropathy associated T-cell lymphoma (n=18), and monomorphic epitheliotropic intestinal T-cell lymphoma (n=2). Associations of DTI with clinical factors and outcomes were examined using Kaplan Meier and Cox models. Event free survival (EFS) was defined as the time from start of treatment to relapse/progression, start of 2nd line therapy, or death from any cause. Overall survival (OS) was defined as the time from start of treatment until death from any cause. DTI was defined as the number of days between the first diagnostic biopsy and the start of therapy. Patients who were initially observed or had DTI > 100 days were excluded. Results In 559 patients (229 MER and 330 LEO), median age was 60, 34% had IPI>2 and 71% were stage III/IV. 472 (84%) patients initially received anthracycline-based chemotherapy. Median DTI was 23 days (interquartile range (IQR): 12-39) and was similar in MER (21 days, IQR: 11-33) and LEO (25 days, IQR: 14-42). 168 (30%) patients had DTI 0-14 days, 178 (32%) 15-28 days, and 213 (38%) 29-100 days. Overall in the cohort, shorter DTI was associated with a worse 5-year OS (DTI 0-14 days: 43%; DTI 15-28 days: 53%; DTI 29-100 days: 58%, p<0.001) and 5-year EFS (DTI 0-14 days: 31%; DTI 15-28 days: 39%; DTI 29-100 days: 45%, p<0.001). In multivariable analyses, the association of DTI with outcomes remained consistent after adjusting for age and International Prognostic Index (IPI). Shorter DTI was strongly associated with adverse clinical factors, including elevated lactate dehydrogenase levels, poor performance status, B-symptoms, and higher IPI in both cohorts (all P < .003). DTI was not associated with age, sex, or distance from the LEO/MER center (all p>0.3). 6% patients with DTI of 0-14 days received 1L treatment on a clinical trial, compared to 11% with DTI 15-28 days and 13% with DTI 29-100 days, underscoring that patients with lower DTI may be underrepresented in clinical trials. When examining within PTCL subtypes, the association between short DTI (0-14 days) and inferior outcomes was most prominent in PTCL, NOS (OS HR=2.13, 95% CI: 1.52-2.94; EFS HR =1.49, 95% CI: 1.19-1.85). Associations between short DTI and outcomes were weaker in other subtypes: nTFHL (OS HR=1.28, 95% CI: 0.83-2.00; EFS HR =1.22, 95% CI: 0.82-1.81), ALCL, ALK-, (OS HR=1.30, 95% CI: 0.59-2.86; EFS HR =1.32, 95% CI: 0.68-2.56), ALCL, ALK+, (OS HR=1.05, 95% CI: 0.26-4.17; EFS HR =2.12, 95% CI: 0.84-5.26). Conclusion Shorter DTI is associated adverse prognostic clinical factors (LDH, stage, high IPI) and inferior EFS and OS in newly diagnosed PTCL. Patients with DTI ≤ 14 days, which represents approximately 1/3 patients with PTCL, may be underrepresented in clinical trials. Understanding of this selection bias should inform clinical trial design and interpretation. Future studies should consider strategies to minimize barriers to enrollment for patients with low DTI.
Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient chara
Ali, Amir , Torka, Pallawi , Graff, Tara , Mulvey, Erin , Zhang, Yumeng , Jun, Monika, Mutebi, Alex , Tybor, David J. , Huynh, Lynn , Lax, Angela , Branchcomb, Tychell, Duh, Mei Sheng , Wang, Yucai , Alshreef, Abualbishr , Wang, Anthony , Tybor, David, Muñoz, Javier , Moustafa, Muhamad Alhaj , Ahmed, Nausheen

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 8075-8075

10.1182/blood-2025-8075 Get It

Abstract Introduction: Epcoritamab (epcor) was the first CD3xCD20 bispecific antibody approved for treatment of R/R DLBCL in May 2023 based on its efficacy and safety in EPCORE NHL-1. Patients (pts) enrolled in clinical trials are highly selected, and those with high-risk features, such as primary refractory disease, early post-CAR T relapse, poor Eastern Cooperative Oncology Group (ECOG) performance status (PS), and CD20+ status are often underrepresented or excluded. As epcor use expands in more heterogeneous, real-world populations, there is increasing interest in understanding pt characteristics and response outcomes associated with its use outside of clinical trials. In particular, pts with DLBCL that is resistant to, or relapse soon after, CAR T are left with limited treatment options and often present with rapidly progressive, resistant disease, making them especially challenging to manage. Generating real-world evidence is critical for informing optimal use of epcor in routine practice. Methods: Real-EPCOR is a multicenter US retrospective chart review study at >8 academic and community oncology centers designed to evaluate the real-world use of epcor. Eligible pts are adults (≥18 years) with R/R DLBCL and ≥2 prior lines of therapy (LOT) who initiated epcor outside of a clinical trial after 5/19/23. Pt demographic, clinical, and treatment data were collected, including ECOG PS, refractory status, prior CAR T, and CD20+ status. Overall response rate (ORR) was evaluated during epcor treatment and defined as the proportion of pts achieving complete response (CR) or partial response among pts with ≥1 evaluable response assessment or who died due to disease progression before response assessment. ORR and CR rate were calculated for the entire cohort, for pts receiving ≥2 cycles of epcor (full cycle is 28 days), and for pts who received prior CAR T. Results: This interim analysis included 34 pts from 2 centers. Data collection and analysis is ongoing and updated results with additional pts and longer follow-up may be included at time of presentation. Median age was 67 years; 68% pts were male and 85% were White. Median time from DLBCL diagnosis to initiation of epcor was 15.5 months. The most common comorbidities were cardiovascular disease (59%) and diabetes mellitus (29%). ECOG PS was ≥2 in 29% of pts, and 85% of pts had Ann Arbor stage 3-4 disease. Nearly all (97%) had CD20+ DLBCL. High-risk features were common at time of epcor initiation, including 53% with International Prognostic Index (IPI) ≥3, 26% with double-hit, and 24% with non-GCB subtype. Among pts who received ≥2 cycles of epcor (n=15), 20% had ECOG PS ≥2 and 33% had IPI ≥3; in post-CAR T pts, 22% had ECOG PS ≥2 and 57% had IPI ≥3. Median number of prior LOT was 3 (range: 2–9); 44% of pts initiated epcor as 3L therapy. Prior to epcor, 41% had primary refractory disease. Following their most recent therapy, 72% had refractory disease, and 43% had DLBCL that was refractory to all prior LOT in those with known refractory status. Most pts (68%) received prior CAR T, with a median interval of 4.6 months from infusion to epcor initiation, and 23% initiated epcor ≤2 months from CAR T. 15 pts (44%) received CAR T in the LOT immediately prior to epcor, 9 (60%) of whom were refractory to CAR T. The ORR was 50% and CR rate was 29% in the overall evaluable population (n=24). 10 pts were not evaluable, as they did not undergo a response assessment either because they remained alive without assessment or experienced a non-progression-related event. Among pts who received ≥2 cycles of epcor, ORR was 85% and CR rate was 54% in the evaluable population (n=13). Among 23 post-CAR T pts, ORR was 53% and CR rate was 33% in the evaluable population (n=15). Conclusion: In this real-world interim analysis, pts with R/R DLBCL treated with epcor had a high proportion of CD20+ disease, higher-risk clinical features, greater comorbidity burden, and more complex treatment histories, including a substantial proportion with prior CAR T, compared to pts in EPCORE NHL-1. Therefore, the ORR remains highly meaningful in the overall cohort despite being lower than the trial. Encouraging ORRs among those who received ≥2 cycles of epcor or had prior CAR T suggest that epcor monotherapy may provide clinical benefit even in difficult-to-treat pts in the real-world setting. Ongoing real-world survival analyses will inform the optimal use of epcor within the evolving treatment landscape of R/R DLBCL.
Outcomes in the 2nd decade following follicular lymphoma (FL) diagnosis: Long-term follow-up from the university of Iowa/Mayo Clinic SPORE molecular epidemiology resource (MER)
Thompson, Carrie A. , Flowers, Christopher R. , Ansell, Stephen M. , Day, Jonathan, Larson, Melissa C. , Mou, Eric , Durani, Urshila , Casulo, Carla , Tsang, Mazie , Farooq, Umar , Mondello, Patrizia , Villasboas, José C. , Syrbu, Sergei , Feldman, Andrew L. , Witzig, Thomas E. , Habermann, Thomas M. , Cerhan, James R. , Link, Brian K. , Wang, Yucai , Maurer, Matthew J.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1007-1007

10.1182/blood-2025-1007 Get It

Abstract Introduction: Outcomes for FL have markedly improved, and the 10-year (yr) overall survival (OS) for patients (pts) diagnosed in the rituximab era is about 80%. Historically, FL is the leading cause of death in the first decade after diagnosis (dx); however, modern outcomes beyond 10 yrs after dx remain unknown. Here we report long-term outcomes of FL from a large prospective cohort of pts with FL from the rituximab era. Methods: Pts with biopsy-proven FL 1-3A at dx were prospectively enrolled within 9 months of dx from 2002-2015 in the MER. Outcomes of interest were OS, event-free survival (EFS), histologic transformation (HT), and cause of death. HT was defined as subsequent biopsy-proven FL 3B, diffuse large B cell lymphoma, or high-grade B cell lymphoma. Analyses were performed using Cox models and KM curves; cause of death was evaluated using a competing risk approach. A subset analysis was performed in younger (18-59 yrs) vs older (60+ yrs) pts. A landmark analysis was conducted in pts alive at 10 yrs. Results: 1,155 pts with FL 1-3A were enrolled in the MER from 2002-2015. Median age at dx was 60 yrs (IQR 51-69). Clinical characteristics were: 67% stage III/IV, 12% grade 3A, 4% ECOG PS 2-4, and 19% elevated LDH. Initial management was 35% observation (obs), 12% R-monotherapy (R-mono), 39% immunochemotherapy (IC; 43% R-CHOP, 28% R-CVP, 27% BR), and 14% other. FLIPI scores were 40% low, 33% intermediate (int), and 27% high; FLIPI24 risk categories were 49% low, 25% int, and 26% high. At a median follow-up of 14 yrs (IQR 11-18 yrs), 751 events, 148 HTs, and 402 deaths were observed. EFS estimates (95% CI) were: 10-yr: 40% (37-43), 15-yr: 31% (28-35), and 18-yr: 27% (24-31). 15 yr & 18 yr EFS by initial txs were 22% (18-27) & 18% (14-25) for obs, 30% (23-40) & 18% (11-30) for R-mono, and 40% (35-46) & 38% (33-45) for IC. The incidence (95% CI) of HT was 12% (10-14) at 10 yrs, 13% (11-16) at 15 yrs, and 14% (12-17) at 18 yrs. OS (95% CI) for the entire cohort was 77% (75-80%) at 10 yrs, 63% (60-66) at 15 yrs, and 55% (51-59) at 18 yrs. The incidence of non-lymphoma-related death (non-LRD) surpassed lymphoma-related death (LRD) after 12 yrs in pts with known cause of death. Estimates (95% CI) for LRD were 11% (10-13) at 10 yrs, 14% (12-17) at 15 yrs, and 16% (14-19) at 18 yrs, while estimates for non-LRD were at 8% (7-10) at 10 yrs, 17% (15-20) at 15 yrs, and 22% (19-26) at 18 yrs. Among pts diagnosed before age 60, LRD remained the predominant cause of mortality into the second decade following dx, with incidences (95% CI) of LRD vs. non-LRD of 7% (5-9) vs 3% (2-4) at 10 yrs, 10% (8-13) vs 5% (3-8) at 15 yrs, and 13% (9-17) vs 6% (4-10) at 18 yrs, respectively. In patients age >60 non-LRD was the predominant cause of mortality in the second decade. Incidence of LRD vs. non-LRD in those aged ≥60 at dx were 15% (13-19) vs 13% (10-16) at 10 yrs, 18% (15-22) vs 28% (24-32) at 15 yrs, and 20% (16-24) vs 35% (31-41) at 18 yrs, respectively. In the landmark analysis of pts alive at 10 yrs from dx (n=720), median age was 69 yrs (IQR 60-77). 63 pts (9%) had HT prior to landmark. The median number of prior treatments was 1 (IQR 1-2, range 1-8). Risk of death (95% CI) was 19% (15-22) in the next 5 yrs (i.e. 15 yrs from dx) and 29% (24-33) in the next 8 yrs (18 yrs from dx). The risk of LRD vs non-LRD was 4% (3-6) vs 12% (9-15) at 5 yrs and 7% (3-9) vs 18% (10-23) at 8 yrs.Conclusions: Long-term outcomes for pts with FL remain excellent into the second decade from dx. HT risk decreases significantly after 10 yrs, though late HTs still occur. At 15 yrs from dx, 40% of pts remained alive and event-free after 1L IC. Nearly a quarter of pts observed at dx remained treatment-free. The most common cause of death after 10 yrs from dx was from non-lymphoma causes, notably in older pts aging into their 70s and 80s. While younger pts have a lower overall risk of LRD compared to older pts, FL represents the leading cause of death in this population during the second decade following dx. These results provide critical insights into the natural history of FL diagnosed in the modern era.
Ponatinib alleviates CAR-T cell exhaustion and remodels the immune microenvironment: A promising combination strategy for relapsed/refractory b-ALL
Zhou, Yi , Wang, Liwen , Xie, Linzhi, Chen, Fangping , He, Rong , Cheng, Qian , Liu, Jing , Li, Xin

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2331-2331

10.1182/blood-2025-2331 Get It

Abstract Background Despite CD19-directed chimeric antigen receptor T (CAR-T) therapy achieving remarkable remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), long-term survival remains constrained by T-cell exhaustion and immunosuppressive microenvironments. Dasatinib, a tyrosine kinase inhibitor (TKI), has been shown to alleviate T cell exhaustion and enhance CAR-T cell persistence, demonstrating therapeutic synergy in newly diagnosed ALL. However, it may also suppress CAR-T cytotoxicity and is ineffective against BCR-ABLT315I mutations. Third-generation TKIs, including ponatinib and olverembatinib, effectively overcome T315I-mediated resistance, yet their impact on CAR-T cell function and immune modulation remains insufficiently defined. Methods and Results: We first established in vitro co-culture models of CD19 CAR-T cells with the B-ALL cell line NALM6 to evaluate the effects of dasatinib, ponatinib and olverembatinib on resting and tumor antigen-activated CAR-T cells. At clinically relevant concentrations, none of the TKIs affected resting CAR-T viability. In contrast, upon activation, all three TKIs significantly inhibited CAR-T activation, cytotoxicity, and cytokine secretion (IL-2, TNF-α, IFN-γ), while reducing activation-induced CAR-T cell apoptosis. TKIs treatment also downregulated exhaustion markers (eg. PD-1, TIM3, LAG3) and promoted differentiation toward naïve (TN) and central memory (TCM) subsets, while reducing terminal effector T cells. After the drug elution, CAR-T cells regained their cytolytic function in response to tumor targets. Notably, ponatinib-treated CAR-T cells exhibited higher levels of IFN-γ, TNF-α and IL-2 post-washout compared to other groups. Importantly, the TN/TCM phenotype and low exhaustion marker expression were preserved after washout in all TKI-treated groups. Transcriptomic profiling of CAR-T cells in vitro revealed that all three TKIs downregulated key exhaustion-associated genes, including PDCD1, HAVCR2, CTLA4 and NR4A1, along with upregulation of stemness- and memory-associated genes (eg. CCR7, TCF7, LEF1, IL7R). Gene set enrichment analysis showed inhibition of T-cell activation, apoptosis, glycolysis, and TGF-β signaling by all TKIs. Remarkably, ponatinib uniquely activated the IFN-γ pathway, suggesting superior immunostimulatory effects. Mechanistically, all three TKIs suppressed the phosphorylation of AKT, p38 MAPK, and NF-κB p65, indicating shared inhibition of downstream TCR signaling. Based on these findings, we evaluated ponatinib in a clinical setting. A prospective study (No. ChiCTR2000036350) enrolled three R/R B-ALL patients with the BCR-ABLT315I mutation. All the patients received CD19 CAR-T cell therapy followed by ponatinib maintenance, initiated two months post-infusion. All three patients remained progression-free during ponatinib maintenance. Notably, the DNA copies of CAR-T cells remained detectable at months 5 and 9 after ponatinib treatment in two patients, respectively. To further explore the in vivo effects of ponatinib on T cells and other immune cells,peripheral blood mononuclear cells were collected from these patients before and one month after ponatinib initiation for single-cell RNA sequencing. Ponatinib exposure led to an increased proportion of CD8+T cells and a decreased abundance of myeloid cells subsets. Within T cells, effector cells expanded while Tregs and exhausted T cells decreased. Differential gene analysis showed suppression of activation, adhesion, apoptosis, and PD-1/PD-L1 signaling, aligning with in vitro results. Functional scoring revealed enhanced cytotoxicity, IFN-γ responses, and reduced glycolysis, exhaustion, TGF-β, and Treg signatures. Furthermore, analysis of NK cell subsets showed enhanced cytolytic scores and enrichment of proliferation and immune activation pathways, suggesting that ponatinib preserves innate immune responses in vivo. Conclusions: This study provides preclinical and preliminary clinical evidence that third-generation TKIs, particularly ponatinib, can effectively alleviate CAR-T cell exhaustion, promote memory phenotypes, and remodel the immune microenvironment. Compared to dasatinib and olverembatinib, ponatinib uniquely enhances effector cytokine production and activates the IFN-γ pathway. These findings support ponatinib as a promising combinatorial agent with CAR-T therapy, offering a rational strategy for improving outcomes in patients with T315I-mutated R/R B-ALL.
Mitochondrial RNA pseudouridine reprograms metabolism and induces immunosuppression in myeloid leukemia
Zhang, Honghai , Wang, Xueer , Ren, Lili , Bi, Hongjie, Xue, Meilin , Wan, Chao‐Ling, Wunderlich, Mark , Mulloy, James C. , Li, Ling , Zhang, Bin , Dong, Lei, Li, Wei Shan , Zhang, Xiaoxu , Ghoda, Lucy Y. , Chen, Chun‐Wei , Rosen, Steven T. , Heisterkamp, Nora , Chen, Jianjun , Kortylewski, Marcin T. , Su, Rui Jun

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 211-211

10.1182/blood-2025-211 Get It

Abstract Pseudouridine (Ψ) is the most prevalent RNA modification in human cells. Although Ψ was among the first post-transcriptional modifications discovered (1951), its biological functions remain poorly understood. More recently, Ψ was incorporated into COVID-19 mRNA vaccine, where it enhances RNA stability and reduces innate immune sensing. However, the precise roles of RNA Ψ in cancer, including leukemia, are largely unknown. Here, we identify RNA Pseudouridine Synthase D4 (RPUSD4) as a novel vulnerability in acute myeloid leukemia (AML) via directly catalyzing mitochondrial RNA (mt-RNA) Ψ formation. We further provide proof-of-concept evidence that targeting RPUSD4 suppresses leukemogenesis and stimulates anti-leukemia immunity. To investigate whether RNA Ψ dysregulation is involved in leukemia, we first compared RNA Ψ levels between primitive CD34+ cells (LSC-enriched) and CD34- bulk cells from multiple primary AML specimens. CD34+ AML cells exhibited significantly elevated RNA Ψ levels. We also examined Ψ levels across various RNA types in AML cells, identifying that mt-RNA contained much higher Ψ levels than other RNA types. These findings imply that RNA Ψ, particularly mt-RNA Ψ, may play a role in LSC biology and leukemogenesis. Further unbiased CRISPR screening revealed RPUSD4 as the most critical Ψ synthase for LSC maintenance. Large-scale transcriptomic and patient data analyses showed that RPUSD4 is highly expressed in AML specimens (P = 3.5 × 10-9), particularly within LSCs (P = 1.4 × 10-18). RPUSD4 knockout (KO) significantly suppressed AML proliferation, reduced mitochondrial OxPhos, and decreased LSC frequency in vitro and substantially delayed AML progression in vivo (MLL-r and FLT3ITD models). Of note, RPUSD4 KO-mediated anti-leukemia effects could be fully rescued by wild-type but not catalytically inactive RPUSD4 both in vitro and in vivo, demonstrating that Ψ synthase activity is essential for its function in leukemia. To profile RPUSD4-dependent Ψ sites, we applied two orthogonal technologies, direct nanopore sequencing and PRAISE sequencing (PMID: 36997645), both capable of detecting Ψ at single-base resolution. These approaches converged on a single RPUSD4-dependent Ψ at position 3,067 on mt-16S rRNA. This Ψ site is essential for maintaining rRNA stability. RPUSD4 KO induced mt-16S rRNA decay, thereby suppressing mitochondrial translation. This led to OxPhos inhibition, growth suppression, and LSC eradication in AML. Mechanistically, RPUSD4 is exclusively localized in mitochondria, where it directly interacts with the mt-RNA exonuclease PNPase. Under physiological conditions, PNPase resides within mitochondria and degrades mt-RNA to prevent accumulation of mitochondrial double-stranded RNA (mt-dsRNA). Upon RPUSD4 depletion, PNPase translocates from mitochondria to the cytosol, resulting in two major consequences: (i) mRNA decay:Cytosolic PNPase degrades mRNAs, particularly the nuclear-encoded mitochondrial mRNAs, such as DHODH(Dihydroorotate dehydrogenase). By retrogradely upregulating DHODH, RPUSD4 promotes de novo pyrimidine synthesis in AML. (ii) Aberrant mt-dsRNA accumulation: The buildup and cytoplasmic release of mt-dsRNA activates “viral mimicry” response that sensitizes AML cells to T cell cytotoxicity. Finally, to therapeutically target RPUSD4, we developed an RNA-based inhibitor, CpG-siRNARPUSD4, by conjugating a specific RPUSD4 siRNA to a Toll-like receptor (TLR9) ligand. CpG-siRNARPUSD4 is specifically internalized by TLR9+ cells, including AML cells, thereby maximizing selectivity and minimizing toxicity. Preclinical studies demonstrate that pharmacologically targeting RPUSD4 significantly prolonged survival across multiple AML models, including patient-derived xenograft (PDX) models, and rendered AML cells more susceptible to T cell–mediated cytotoxicity. Furthermore, the RPUSD4 inhibitor exhibited a promising synergistic effect with DHODH inhibitor in treating relapsed AML in vivo. For instance, in a representative relapsed PDX model, median survival times (in days) were: Ctrl – 28, RPUSD4 inhibitor – 36, DHODH inhibitor – 39, and combination – over 60. In conclusion, our findings uncover a previously unrecognized role of RPUSD4 and mt-RNA Ψ in leukemic metabolism, anti-leukemia immunity, and LSC maintenance. This study also bridges a critical knowledge gap regarding the role of RNA Ψ in leukemogenesis.
Hi-c FFPE sequencing analysis is highly concordant with FISH and detects additional variants informing diagnosis and treatment in diffuse large B-cell lymphoma
Wu, Dehong , Wang, Chang , Visco, Carlo, Chiu, April , Xu, Mina L. , Tam, Wayne , Wen, Shuai, Zu, Youli , Pan, Zenggang , Bernal‐Mizrachi, Leon , Krieken, Joannes H.J.M. Van, Choi, William , Chen, Weina , Ferreri, Andrés J.M. , Moeller, Michael, Sikkink, Kristin , Schmitt, Anthony D. , Zu, Youli , Xu‐Monette, Zijun Y. , Tzankov, Alexandar , Visco, Carlo , Hsi, Eric D. , Dybkær, Karen , Wen, Shuai, Wang, Bangchen , Bhagat, Govind , Montes‐Moreno, Santiago , Ponzoni, Maurilio , Parsons, Benjamin M. , Li, Yong , Hastie, Alex R. , Young, Ken H.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3529-3529

10.1182/blood-2025-3529 Get It

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for approximately 30% of all NHL cases. DLBCL diagnosis relies on histologic examination, immunophenotyping, molecular and fluorescence in situ hybridization (FISH) analysis to differentiate it from similar NHL subtypes with overlapping morphological features, including more high-grade lymphomas like double-hit lymphoma. Because FISH is performed in a panel of single- or dual-target test format and analyzed through microscopy and manual image analysis, assessment of multiple target biomarkers can be cumbersome and expensive. As additional biomarkers for diagnosis, subtyping, prognosis, and therapeutic decision-making become available, target panels will become larger, posing additional challenges to clinical laboratories. Patients and Methods In this study, Hi-C sequencing of FFPE samples was performed to identify all genomic rearrangements by a single sequencing analysis for an unselected DLBCL case series of 159 patients, and the results were compared to FISH for the detection of clinically important variants. Results Hi-C sequencing showed superior performance compared to FISH: standard FISH for DLBCL includes testing for MYC, BCL2, and BCL6. Between FISH and Hi-C, these biomarkers were detected 105 times, of which, FISH detected 80/105 (76%) and Hi-C detected 102/105 (97%). The cohort included 4 double-hit lymphomas by FISH but Hi-C sequencing detected five. Besides DLBCL diagnostic biomarkers (MYC, BCL2, BCL6), many additional biomarkers were detected by Hi-C sequencing including variants not tested by FISH because the clinical suspicion was ambiguous and the relevant FISH probes were not used, and those not tested because the biomarkers were not thought to be common and, hence, left out of the FISH panel. In total, Hi-C sequencing detected additional biomarkers in 42 (26%) cases, including (1) variants targeted by FISH (i.e. MYC, BCL2, BCL6) but negative, (2) classification biomarkers for other lymphomas (CCND1, MALT, IRF4), and (3) those not tested because the biomarkers are not common and not included in the FISH panel. These additional biomarkers were supportive of suspected diagnosis of DLBCL versus double-hit lymphoma (24 cases), prompted reconsideration of a different diagnosis that may have led to different treatments (6 cases, e.g. mantle cell lymphoma), or biomarkers such as PDL1, ALK, and ATM which have implications for targeted therapies and/or inclusion in clinical trials (5 cases). Conclusion The Hi-C FFPE sequencing technology has the potential to improve the workflow of pathology labs for detection of a wide range of structural variants informing precision diagnosis and treatment for lymphomas.
Redefining the myeloid disease continuum: Machine learning–based development and validation of an integrated multimodal classification of myeloid neoplasms
Gurashi, Kristian , Mosquera, Adrian, Maciejewski, Jaroslaw, Telford, Nick , Batta, Kiran , Wang, Yu‐Hung , Lin, Chien‐Chin , Gurnari, Carmelo , Awada, Hussein , Mosquera, Adrian, Pérez‐Encinas, Manuel , McLornan, Donal P. , Žučenka, Andrius , Badar, Talha , Ko, Bor‐Sheng , Hou, Hsin‐An , Chou, Wen‐Chien , Tien, Hwei‐Fang , Wiseman, Daniel H.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4347-4347

10.1182/blood-2025-4347 Get It

Abstract Introduction The 2022 WHO/ICC classifications of myeloid neoplasms (MNs) incorporated genomics into the existing clinicopathologic framework, defining new (mono)genetic entities. However, this iterative approach resulted in a mix of pathologically and genomically-defined entities, reliant on arbitrary thresholds and historically-derived boundaries between entities. We hypothesised that integrating genomics with other features, de novo from first principles, might better incorporate modern molecular knowledge to define the biological continuum, evolutionary links and overlapping features across MN. Methods The discovery cohort comprised 6484 thoroughly annotated pts. Contemporary diagnoses included 1817 AML, 1695 MDS, 737 MPN, and 1101 MDS/MPN. Non-malignant pts (AA/CHIP/CCUS/ICUS) were included to explore beyond current neoplastic boundaries. 1407 pts had ≥1 follow-up sample/s. Validation was performed in an independent international cohort (n=2012). An unsupervised random forest algorithm was used to integrate status (and VAF) for 28 mutations, karyotypes, CBC features, sex and age (total parameters 144). Features were selected for potential to be independent of BM sampling. Proximity-based multidimensional scaling/PCA were used to visualize latent structure and identify variance-driving features. Results The model projected pts onto a continuous 3-dimensional space. We first applied clustering seeking 1st-order structure, revealing 4 major clusters (C1–C4). These were further subdivided into 58 distinct subclusters (SCs) by an unsupervised iterative clustering approach. All SCs were enriched for distinctive features, with diverse associations linking genomics to clinicopathological/outcome features. Notably, contemporary diagnoses were distributed widely throughout this landscape, with 9/58 SCs containing cases spanning multiple WHO/ICC MN categories. C1 displayed the most internal heterogeneity, with admixed AML, MDS and MDS/MPN pts. It naturally subdivided down to 4th-order subclustering. Ten SCs were dominated by splicing factor mutations. For example, SF3B1MT segregated into 3 SCs, alone or with high-VAF TET2/ASXL1 or DNMT3A mutations. A separate TET2/SRSF2 SC associated with elevated monocyte%, reflecting a discrete CMML-phenotype genomic entity. NPM1MT formed a distinct SC with FLT3-ITD, distinguished further by VAFs of FLT3, TET2, and NRAS. Current genomically-defined AML subtypes separated in the 4th subclustering. C2 encompassed classical MPN driver mutations across 6 SCs, including a distinct CALRMT group and others defined by variable JAK2 VAFs, co-mutation patterns and other CBC features: eg high-VAF SF3B1MT correlated with PB blast%, and concurrent TET2MT with higher Hb/monocyte counts. C3 was characterized by TP53 alterations, with 5 SCs differing by TP53MT burden, 17p lesions, karyotypic complexity and age. Two SCs, one marked by high TP53 VAF+complex karyotype, the other by ch17 lesions, were associated with the worst OS in the whole cohort. C4 contained most known non-malignant pts, dividing into 4 SCs: 2 largely comprising CCUS and AA, while 2 reflect overlaps/convergence between AA and MDS and MPN, respectively. Repurposing single-cell pseudotime analysis suggested multiple disease origins, with various progression trajectories converging on C3. Projecting them onto the model longitudinal samples moved along these derived paths, consistent with their known progression/remission changes, validating the model's biological relevance and predictive utility. Remarkably, the 58 SCs displayed distinct risks of clonal progression and survival. To maximize potential clinical utility we created a pan-MN prognostic score integrating these features. It performed robustly (c-index 0.84), matching/exceeding existing prognostic tools and validated in an independent dataset. Conclusion Integrating clinicopathologic and genomic data we developed ab initio a continuum model of MNs that transcends historical diagnostic boundaries, captures disease evolution and stratifies clinical outcomes. It may better reflect the core biology and natural histories of specific cases, placing more rational boundaries between discrete entities. Potential advantages extend to treatment selection/trial design (in the era of molecularly-targeted therapies) and personalised prognostication throughout each disease course. Expanded validation is needed to resolve complexity in some areas (notably in C2/C4) and validate/refine this prototype framework.